# Rinzimetostat

Source: https://onco.cc/drugs/rinzimetostat/  
OnCo record `rinzimetostat` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rinzimetostat is an experimental small-molecule drug from ORIC Pharmaceuticals in phase 3 trials for prostate cancer, with its target not yet stated publicly.

## Summary

Rinzimetostat (ORIC-944) is a small-molecule drug developed by ORIC Pharmaceuticals. The sponsor describes its target as PRC2 (EED subunit), which OnCo does not yet have a target page for. The sponsor states: A potent and selective allosteric inhibitor of Polycomb Repressive Complex 2 (PRC2) acting via the EED subunit, intended to provide advantages over EZH2-targeted approaches. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07723248 (A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)), in prostate cancer. The largest, NCT07723248, plans to enrol 600 participants with primary completion expected 2028-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: ORIC-944
- Modality: small molecule
- Mechanism: A potent and selective allosteric inhibitor of Polycomb Repressive Complex 2 (PRC2) acting via the EED subunit, intended to provide advantages over EZH2-targeted approaches.

## Sources

- ClinicalTrials.gov: trials of Rinzimetostat: https://clinicaltrials.gov/search?intr=ORIC-944
- Sponsor pipeline page: https://oricpharma.com/pipeline/

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [ORIC Pharmaceuticals](https://onco.cc/companies/oric-pharmaceuticals/)
- trials: [A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)](https://onco.cc/trials/himalayas-1/)
- targets: [EED](https://onco.cc/targets/eed/)

---
JSON: https://onco.cc/api/v1/entities/rinzimetostat.json